Benign Prostatic Hyperplasia: Does Prostate Size Matter?

Overview

Journal Rev Urol

Date 2006 Sep 21

PMID 16985958

Citations 15

Authors

J Curtis Nickel

Affiliations

Soon will be listed here.

Abstract

Recent studies and analyses have confirmed that baseline prostate volume is related to progression of benign prostatic hyperplasia (BPH) as well as to negative outcomes related to BPH, such as acute urinary retention (AUR) and need for surgery, and can also predict response to therapy. Other investigations have determined that prostate-specific antigen (PSA) level has good predictive value for assessing prostate volume. Strong evidence exists that baseline serum PSA level, like baseline prostate volume, predicts future prostate growth. Randomized placebo-controlled finasteride trials have shown that men with larger prostate volumes and higher PSA levels experience a clinically significant response to therapy compared with those with smaller prostate volumes and lower PSA levels. It has also been demonstrated that men with larger prostate glands and higher PSA levels are at increased risk for AUR and BPH-related surgery but that finasteride reduces these risks. Moreover, doxazosin and finasteride, alone and in combination, have been shown to significantly reduce BPH clinical progression.

Citing Articles

Long-term results of multimodal treatment of the prostate using the Thulium Laser.

Coman R, Leucuta D, Coman R, Lapusan C, Stanca D, Coman I Med Pharm Rep. 2024; 97(3):338-346.

PMID: 39234455 PMC: 11370861. DOI: 10.15386/mpr-2760.

Long-term functional outcomes and surgical retreatment after thulium laser enucleation of the prostate: A 10-year follow-up study.

Manfredi C, Napolitano L, Ditonno F, Fusco G, Quattrone C, De Sio M Int Braz J Urol. 2024; 50(3):309-318.

PMID: 38446905 PMC: 11152334. DOI: 10.1590/S1677-5538.IBJU.2024.0039.

Prostatic artery occlusion: initial findings on pathophysiological response in a canine prostate model.

Lucas-Cava V, Sanchez-Margallo F, Moreno-Lobato B, Davila-Gomez L, Lima-Rodriguez J, Garcia-Martinez V Transl Androl Urol. 2023; 11(12):1655-1666.

PMID: 36632152 PMC: 9827397. DOI: 10.21037/tau-22-423.

Transrectal Ultrasound in Prostate Cancer: Current Utilization, Integration with mpMRI, HIFU and Other Emerging Applications.

Panzone J, Byler T, Bratslavsky G, Goldberg H Cancer Manag Res. 2022; 14:1209-1228.

PMID: 35345605 PMC: 8957299. DOI: 10.2147/CMAR.S265058.

Current surgical procedures for benign prostatic hyperplasia and impression of new surgical modalities.

Al Khayal A, Balaraj F, Alferayan T, Alrabeeah K, Abumelha S Urol Ann. 2021; 13(2):95-100.

PMID: 34194132 PMC: 8210715. DOI: 10.4103/UA.UA_75_20.

References

Jacobsen S, Girman C, Guess H, Rhodes T, Oesterling J, Lieber M . Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol. 1996; 155(2):595-600. DOI: 10.1016/s0022-5347(01)66461-9. View

Roehrborn C, Boyle P, BERGNER D, Gray T, Gittelman M, Shown T . Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology. 1999; 54(4):662-9. DOI: 10.1016/s0090-4295(99)00232-0. View

Roehrborn C, Bruskewitz R, Nickel G, GLICKMAN S, Cox C, Anderson R . Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group. Eur Urol. 2000; 37(5):528-36. DOI: 10.1159/000020189. View

de la Rosette J, Kortmann B, Rossi C, Sonke G, Floratos D, Kiemeney L . Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. J Urol. 2002; 167(4):1734-9. DOI: 10.1097/00005392-200204000-00035. View

Marberger M, Andersen J, Nickel J, Malice M, Gabriel M, Pappas F . Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. Eur Urol. 2000; 38(5):563-8. DOI: 10.1159/000020356. View

Jacobsen S, Jacobson D, Girman C, Roberts R, Rhodes T, Guess H . Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997; 158(2):481-7. DOI: 10.1016/s0022-5347(01)64508-7. View

Roehrborn C . Reducing the risk of benign prostatic hyperplasia progression. Rev Urol. 2006; 4 Suppl 5:S29-38. PMC: 1476011. View

Arrighi H, Guess H, Metter E, Fozard J . Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate. 1990; 16(3):253-61. DOI: 10.1002/pros.2990160309. View

Gormley G, Stoner E, Bruskewitz R, Imperato-McGinley J, Walsh P, McConnell J . The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992; 327(17):1185-91. DOI: 10.1056/NEJM199210223271701. View

10.

Roehrborn C, Girman C, Rhodes T, Hanson K, Collins G, Sech S . Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology. 1997; 49(4):548-57. DOI: 10.1016/s0090-4295(97)00031-9. View

11.

Lepor H, Williford W, Barry M, Brawer M, DIXON C, Gormley G . The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med. 1996; 335(8):533-9. DOI: 10.1056/NEJM199608223350801. View

12.

Roehrborn C, Boyle P, Gould A, Waldstreicher J . Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999; 53(3):581-9. DOI: 10.1016/s0090-4295(98)00655-4. View

13.

Jacobsen S, Jacobson D, Girman C, Roberts R, Rhodes T, Guess H . Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol. 1999; 162(4):1301-6. View

14.

Roberts R, Jacobsen S, Jacobson D, Rhodes T, Girman C, Lieber M . Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol. 1999; 163(1):107-13. View

15.

Bruskewitz R, Girman C, Fowler J, RIGBY O, Sullivan M, Bracken R . Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology. 1999; 54(4):670-8. DOI: 10.1016/s0090-4295(99)00209-5. View

16.

Roehrborn C, McConnell J, Bonilla J, Rosenblatt S, Hudson P, Malek G . Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol. 1999; 163(1):13-20. View

17.

Emberton M, Andriole G, de la Rosette J, Djavan B, Hoefner K, Navarrete R . Benign prostatic hyperplasia: a progressive disease of aging men. Urology. 2003; 61(2):267-73. DOI: 10.1016/s0090-4295(02)02371-3. View

18.

Boyle P, Gould A, Roehrborn C . Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology. 1996; 48(3):398-405. DOI: 10.1016/s0090-4295(96)00353-6. View

19.

McConnell J, Bruskewitz R, Walsh P, Andriole G, Lieber M, HOLTGREWE H . The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998; 338(9):557-63. DOI: 10.1056/NEJM199802263380901. View

20.

Roehrborn C, McConnell J, Lieber M, Kaplan S, Geller J, Malek G . Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology. 1999; 53(3):473-80. DOI: 10.1016/s0090-4295(98)00654-2. View